Checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1 [110] or anti-PDL-1 [111] have been covalently attached to NPs to activate an immune response in GBM; also cytokines have been loaded into NPs to treat GBM [112]. The gene discussed is CTLA4; the disease is glioblastoma.